Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 12/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ABL2 | P42684 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 3/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603491 | 0.88 | EGFR (0.51) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL6186460 | 0.75 | ALDH1A1 (0.47) | NPC1RAB9AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11869172 | 0.74 | ESR1 (0.60) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL27130686 | 0.73 | DYRK1A (0.46) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL29580246 | 0.72 | ALDH1A1 (0.49) | NPC1RAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20562958 | 0.72 | CYP2A6 (0.57) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL20562957 | 0.72 | CYP2A6 (0.57) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL7547842 | 0.72 | ESR1 (0.44) | NPC1RAB9AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15969643 | 0.72 | DYRK1A (0.45) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5539641 | 0.72 | DYRK1A (0.45) | NPC1RAB9AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237717-A1 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds | Opal Biosciences Limited (AU) | 2020-07-30 | — | — | US | claimed |
| EP-3661496-A1 | TREATMENT OF STAPHYLOCOCCAL AND ENTEROCOCCAL INFECTIONS USING SUBSTITUTED NITROSTYRENE COMPOUNDS | Opal Biosciences Limited (AU) | 2020-06-10 | — | — | EP | claimed |
| WO-2019023741-A1 | TREATMENT OF STAPHYLOCOCCAL AND ENTEROCOCCAL INFECTIONS USING SUBSTITUTED NITROSTYRENE COMPOUNDS | Opal Biosciences Limited (AU) | 2019-02-07 | — | — | WO | claimed |
| US-20140080876-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2014-03-20 | — | — | US | claimed |
| CN-101804047-B | Antimicrobial and radioprotective compounds | BIODIEM LTD | 2012-12-26 | — | — | CN | claimed |
| CN-101804047-A | Antibiotic and Radioprotector compounds | BIODIEM LTD | 2010-08-18 | — | — | CN | claimed |
| CN-1863788-B | Antibacterial and radioprotective compounds | BIODIEM LTD | 2010-05-12 | — | — | CN | claimed |
| EP-1404665-A4 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2007-06-27 | — | — | EP | claimed |
| CN-1863788-A | Antibacterial and radioprotective compounds | BIODIEM LTD (AU) | 2006-11-15 | — | — | CN | claimed |
| US-20060100258-A1 | Growth promotion method | BIODIEM LTD. (AU) | 2006-05-11 | — | — | US | claimed |
| CN-1753875-A | Growth promotion method | BIODIEM LTD (AU) | 2006-03-29 | — | — | CN | claimed |
| EP-1597236-A1 | GROWTH PROMOTION METHOD | Biodiem Ltd. (AU) | 2005-11-23 | — | — | EP | claimed |
| US-20040266844-A1 | Antimicrobial and radioprotective compounds | BIODIEM LTD (AU) | 2004-12-30 | — | — | US | claimed |
| WO-2004076423-A1 | GROWTH PROMOTION METHOD | BIODIEM LTD (AU) | 2004-09-10 | — | — | WO | claimed |
| EP-1404665-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | Biodiem Ltd. (AU) | 2004-04-07 | — | — | EP | claimed |
| WO-2002102789-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2002-12-27 | — | — | WO | claimed |
| US-20200237717-A1 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds | Opal Biosciences Limited (AU) | 2020-07-30 | — | — | US | disclosed |
| US-9867802-B2 | Method of treating Scedosporium spp. infection | BIODIEM LIMITED (AU) | 2018-01-16 | — | — | US | disclosed |
| EP-1404665-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | Biodiem Ltd. (AU) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002102789-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237717-A1 | Treatment of Staphylococcal and Enterococcal Infections Using Substituted Nitrostyrene Compounds | APP, AHR, ESD | FBP1 3205/4885EGFR 1363/4885ABL1 3616/4885 |
| US-20040266844-A1 | Antimicrobial and radioprotective compounds | VIP, XPA, ERCC4 | FBP1 581/4885EGFR 1738/4885ABL1 2804/4885 |
| US-20140080876-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | FBP1 1139/4885EGFR 1313/4885ABL1 2850/4885 |
| US-20060100258-A1 | Growth promotion method | HDGF, MKI67, GHRHR | FBP1 2178/4885EGFR 58/4885ABL1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.